Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Stereotaxis Q3 2026 Results: Net Loss of $6.48M, Loss Widens

Stereotaxis reported total revenue of $8.9 million for the third quarter of 2026, an increase from $7.5 million in the prior year, though year-to-date revenue declined slightly to $22.9 million. The company recorded a net loss of $16.8 million for the first nine months of 2026, impacted by increased research and development costs and the acquisition of Robocath. Total assets grew significantly to $82.1 million, primarily due to increases in goodwill and insurance receivables.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue8.97.5
Gross profit4.04.1
Net income-6.5-6.5
EPS (diluted, $ a share)$-0.07$-0.07

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+19.6%
Gross margin44.3%
Operating margin-72.5%
Source

10-Q filed with the SEC, NYSE: STXS. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Stereotaxis, Inc.: key numbers

Share price
$0.8027Close, Nov 16
Market cap
$81M
Shares outstanding
100.86MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Electromedical & Electrotherapeutic ApparatusSIC 3845

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Stereotaxis, Inc.

All →
4:07 PM ET 8-K
Loan & Debt

Stereotaxis $24M Debt Financing with certain accredited investors

Stereotaxis entered into a Note Purchase Agreement to issue up to $24.0 million in convertible promissory notes, with an initial $12.0 million closing on November 9, 2026. The notes bear 10% interest, mature in three years, and are convertible into common stock at an initial price of $1.21 per share.

Value
$24M
Counterparty
certain accredited investors
Term
3 years

“Our near-term priority is to drive forward two major business model transformations. The first is shifting from capital systems that require long sales and construction timelines, to having a portfolio of systems that are significantly more accessible and scalable. The second is developing and commercializing a portfolio of disposable interventional catheters that enhance the value of our robots and provide a robust recurring revenue opportunity.”

David Fischel, Chairman and CEO

“System revenue of $3 million in the quarter was up 60% compared to last year, benefiting from partial revenue recognition from the first GenesisX system in the US, the first Genesis system in China, and multiple Synchrony digital operating room systems in the US.”

David Fischel, Chairman and CEO

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.